Pioglitazone Protects Mesenchymal Stem Cells against P-Cresol-Induced Mitochondrial Dysfunction via Up-Regulation of PINK-1
Mesenchymal stem cells (MSC) could be a candidate for cell-based therapy in chronic kidney disease (CKD); however, the uremic toxin in patients with CKD restricts the therapeutic efficacy of MSCs. To address this problem, we explored the effect of pioglitazone as a measure against exposure to the ur...
Main Authors: | Yeo Min Yoon, Yong-Seok Han, Chul Won Yun, Jun Hee Lee, Rang Kim, Sang Hun Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-09-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | http://www.mdpi.com/1422-0067/19/10/2898 |
Similar Items
-
Co-Administration of Melatonin Effectively Enhances the Therapeutic Effects of Pioglitazone on Mesenchymal Stem Cells Undergoing Indoxyl Sulfate-Induced Senescence through Modulation of Cellular Prion Protein Expression
by: Yong Seok Han, et al.
Published: (2018-05-01) -
Potential Therapeutic Strategy in Chronic Obstructive Pulmonary Disease Using Pioglitazone-Augmented Wharton's Jelly-Derived Mesenchymal Stem Cells
by: Jin-Soo Park, Ph.D, et al.
Published: (2019-04-01) -
Temporal integration of mitochondrial stress signals by the PINK1:Parkin pathway
by: J. Logan Bowling, et al.
Published: (2019-08-01) -
Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells
by: Marie Saghaeian Jazi, et al.
Published: (2016-07-01) -
Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis
by: Yiqiang Hu, et al.
Published: (2021-05-01)